Key result
Asymptomatic HCM linked to ~1.4-point higher median HCM Risk-SCD score than symptomatic patients.
Why the study?
Functional status and the HCM Risk-SCD score are key parameters guiding hypertrophic cardiomyopathy management, prompting an assessment of the relationship between functional status, comorbidity burden, and the HCM Risk-SCD score.
Does functional status (NYHA class) or comorbidity burden correlate with the estimated HCM Risk-SCD score in patients with hypertrophic cardiomyopathy?
Cohort (n=56)
No
Does functional status (NYHA class) or comorbidity burden correlate with the estimated HCM Risk-SCD score in patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Asymptomatic HCM patients may have a higher estimated sudden cardiac death risk score than symptomatic patients, independent of comorbidity burden, highlighting the need for thorough SCD risk stratification even in patients with good functional status.
Introduction Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder associated with heart failure, arrhythmias, and an increased risk of sudden cardiac death (SCD). Functional status and the HCM Risk-SCD score are key parameters guiding management. This study assessed the relationship between functional status, comorbidity burden, and the HCM Risk-SCD score in patients with HCM. Material and methods This retrospective single-cohort study included 56 patients with HCM. The HCM Risk-SCD score was calculated according to the 2023 ESC guidelines. Patients were stratified by heart failure symptoms into asymptomatic (NYHA I) and symptomatic (NYHA II–III) groups, and by comorbidity burden into low (0–1) and high (≥2) groups. Assessed comorbidities included systemic hypertension, hyperlipidemia, coronary artery disease, chronic kidney disease, COPD, and type 2 diabetes. Results The median HCM Risk-SCD score was higher in asymptomatic than symptomatic patients (3.46% [IQR 2.38-4.44] vs. 2.07% [IQR 1.17-2.23]; p=0.005). No significant difference was observed between patients with low and high comorbidity burden (1.95% vs. 2.01%; p=0.765), and no correlation was found between the HCM Risk-SCD score and the number of comorbidities (rho=-0.07, p=0.607). Conclusions Asymptomatic patients with HCM had a higher estimated risk of SCD than symptomatic patients. The HCM Risk-SCD score appeared to be independent of comorbidity burden. This shows that HCM individuals with better clinical and functional status may be at higher risk of SCD.
No takes yet. Share an insight, caveat, or question.
Krywult et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (HCM) (n=56). Asymptomatic functional status (NYHA class I) vs. Symptomatic functional status (NYHA class II-III) was evaluated on Median HCM Risk-SCD score (calculated per 2023 ESC guidelines) (p=0.005). Asymptomatic HCM patients (NYHA I) had a higher median HCM Risk-SCD score than symptomatic patients (NYHA II-III), independent of comorbidity burden.
Synapse has enriched 10 related papers. Consider them for comparative context: